Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Michael

Showing results (141-150 of 216) with videos related to

Pageof 22
Sort By:
Asia-Pacific Journal of Clinical Oncology|March 1, 2014
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCMichael Michael, Shane C White, Ehtesham Abdi, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2020
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (<sup>18</sup> F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumorsMei Sim Lung, Rodney J Hicks, Nick Pavlakis, et al.
Targeted Oncology|June 8, 2017
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerMichael Michael, Yung-Jue Bang, Young Suk Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathyIan D Davis, Lynette Kiers, Lachlan MacGregor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 22, 2018
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2019
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and ParagangliomaGrace Kong, Tess Schenberg, Christopher J Yates, et al.
Diseases of the Colon and Rectum|March 20, 2021
Synchronous Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Liver and Peritoneal Metastases: A Systematic Review and Meta-analysisMichael P Flood, Atandrila A Das, Mikael L Soucisse, et al.
Contemporary Clinical Trials Communications|October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)Toan Pham, Lloyd Pereira, Sara Roth, et al.
Acta Oncologica (Stockholm, Sweden)|January 25, 2014
Impact of advancing age on treatment and outcomes in anal cancerMarcus Foo, Emma Link, Trevor Leong, et al.
ANZ Journal of Surgery|May 9, 2022
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centreMichael P Flood, Vignesh Narasimhan, Peadar S Waters, et al.
Pageof 22

Showing results (141-150 of 216) with videos related to

Sort By:
Pageof 22
Asia-Pacific Journal of Clinical Oncology|March 1, 2014
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCMichael Michael, Shane C White, Ehtesham Abdi, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2020
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (<sup>18</sup> F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumorsMei Sim Lung, Rodney J Hicks, Nick Pavlakis, et al.
Targeted Oncology|June 8, 2017
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerMichael Michael, Yung-Jue Bang, Young Suk Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathyIan D Davis, Lynette Kiers, Lachlan MacGregor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 22, 2018
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2019
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and ParagangliomaGrace Kong, Tess Schenberg, Christopher J Yates, et al.
Diseases of the Colon and Rectum|March 20, 2021
Synchronous Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Liver and Peritoneal Metastases: A Systematic Review and Meta-analysisMichael P Flood, Atandrila A Das, Mikael L Soucisse, et al.
Contemporary Clinical Trials Communications|October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)Toan Pham, Lloyd Pereira, Sara Roth, et al.
Acta Oncologica (Stockholm, Sweden)|January 25, 2014
Impact of advancing age on treatment and outcomes in anal cancerMarcus Foo, Emma Link, Trevor Leong, et al.
ANZ Journal of Surgery|May 9, 2022
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centreMichael P Flood, Vignesh Narasimhan, Peadar S Waters, et al.
Pageof 22